Amiodarone-induced thyroid dysfunction associated with cumulative dose

Pharmacoepidemiology and Drug Safety

Volumn 11, Issue 7, 2002, Pages 601-606

  Bouvy, Marcel L ^a,b   Heerdink, Eibert R ^a   Hoes, Arno W ^c   Leufkens, Hubert G M ^a  

^a UTRECHT UNIVERSITY   (Netherlands)

^b SIR Institute for Pharmacy Practice and Policy   (Netherlands)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Adverse drug reactions; Amiodarone; Hyperthyroidism; Hypothyroidism

Indexed keywords

AMIODARONE; ANTIARRHYTHMIC AGENT; ANTITHYROID AGENT; CARBIMAZOLE; DIGOXIN; LEVOTHYROXINE; LIOTHYRONINE; PROPYLTHIOURACIL; SOTALOL; THIAMAZOLE; THYROMIMETIC AGENT;

ARTICLE; CASE CONTROL STUDY; COHORT ANALYSIS; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACCUMULATION; FEMALE; FOLLOW UP; HEART ARRHYTHMIA; HUMAN; HYPERTHYROIDISM; HYPOTHYROIDISM; MAJOR CLINICAL STUDY; MALE; PRESCRIPTION; PRIORITY JOURNAL; RISK ASSESSMENT; THYROID DISEASE; AGE; CHEMICALLY INDUCED DISORDER; RISK; SEX DIFFERENCE; TIME;

AGE FACTORS; AMIODARONE; ANTI-ARRHYTHMIA AGENTS; CASE-CONTROL STUDIES; COHORT STUDIES; FEMALE; HUMANS; HYPERTHYROIDISM; HYPOTHYROIDISM; MALE; ODDS RATIO; RISK ASSESSMENT; SEX FACTORS; TIME FACTORS;

EID: 0036808080     PISSN: 10538569     EISSN: None     Source Type: Journal    
DOI: 10.1002/pds.735     Document Type: Article

References (17)

1. Chugh SS, Blackshear JL, Shen WK, Hammill SC, Gersh BJ. Epidemiology and natural history of atrial fibrillation: clinical implications. J Am Coll Cardiol 2001; 37: 371-378.
2. Alpert JS. Atrial fibrillation: a growth industry in the 21st century. Eur Heart J 2000; 21: 1207-1208.
3. Hoes AW, Mosterd A, Grobbee DE. An epidemic of heart failure? Recent evidence from Europe. Eur Heart J 1998; 19(Suppl. L): L2-L9.
4. Goldberger JJ. Treatment and prevention of sudden cardiac death: effect of recent clinical trials. Arch Intern Med 1999; 159: 1281-1287.
5. Ramahi TM, Longo MD, Rohlfs K, Sheynberg N. Effect of heart failure program on cardiovascular drug utilization and dosage in patients with chronic heart failure. Clin Cardiol 2000; 23: 909-914.
6. Vorperian VR, Havighurst TC, Miller S, January CT. Adverse effects of low dose amiodarone: a meta-analysis. J Am Coll Cardiol 1997; 30: 791-798.
7. Podrid PJ. Amiodarone: reevaluation of an old drug. Ann Intern Med 1995; 122: 689-700.
8. Hawthorne GC, Campbell NP, Geddes JS, et al. Amiodarone-induced hypothyroidism. A common complication of prolonged therapy: a report of eight cases. Arch Intern Med 1985; 145: 1016-1019.
9. Harjai KJ, Licata AA. Effects of amiodarone, on thyroid function. Ann Intern Med 1997; 126: 63-73.
10. Klein I, Ojamaa K. Thyroid hormone and the cardiovascular system. N Engl J Med 2001; 344: 501-509.
11. Lee KL, Tai YT. Long-term low-dose amiodarone therapy in the management of ventricular and supraventricular tachyarrhythmias: efficacy and safety. Clin Cardiol 1997, 20: 372-377.
12. Martino E, Bartalena L, Bogazzi F, Braverman LE. The effects of amiodarone on the thyroid. Endocr Rev 2001; 22: 240-254.
13. Trip MD, Wiersinga W, Plomp, TA. Incidence, predictability, and pathogenesis of amiodarone-induced thyrotoxicosis and hypothyroidism. Am J Med 1991; 91: 507-511.
14. Herings RM, Bakker A, Stricker BH, Nap G. Pharmaco-morbidity linkage: a feasibility study comparing morbidity in two pharmacy based exposure cohorts. J Epidemiol Community Health 1992; 46: 136-140.
15. Gittoes NJ, Franklyn JA. Hyperthyroidism. Current treatment guidelines. Drugs 1998; 55: 543-553.
16. Bjoro T, Holmen J, Kruger O, et al. Prevalence of thyroid disease, thyroid dysfunction and thyroid peroxidase antibodies in a large, unselected population. The Health Study of Nord-Trondelag (HUNT). Eur J Endocrinol 2000; 143: 639-647.
17. Thorne SA, Barnes I, Cullinan P, Somerville J. Amiodarone-associated thyroid dysfunction: risk factors in adults with congenital heart disease. Circulation 1999; 100: 149-154.